Focused On-demand Library for Serine/threonine-protein kinase PAK 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Beta-PAK; Oligophrenin-3; p21-activated kinase 3

Alternative UPACC:

O75914; A8K389; B1GX77; B1GX78; B1GX79; Q5JWX1; Q5JWX2; Q7Z2D6; Q7Z2E4; Q7Z3Z8; Q8WWK5; Q8WX23; Q9P0J8


Serine/threonine-protein kinase PAK 3, also known as Beta-PAK, Oligophrenin-3, and p21-activated kinase 3, is a pivotal enzyme in various signaling pathways, including cytoskeleton regulation, cell migration, and cell cycle control. It functions as an effector of CDC42 and RAC1 GTPases, influencing dendrite spine morphogenesis, synapse formation, and plasticity. Its kinase activity is essential for phosphorylating MAPK4 and MAPK6, activating MAPKAPK5, and modulating calcium sensitivity through TNNI3 phosphorylation.

Therapeutic significance:

PAK 3's involvement in Intellectual developmental disorder, X-linked 30, underscores its potential as a therapeutic target. Understanding the role of Serine/threonine-protein kinase PAK 3 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.